Susan G. Komen ® Invests Nearly $11 Million to Accelerate Breakthroughs in Breast Cancer Research
DALLAS--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading breast cancer organization, announced today that it is awarding $10.8 million in new research grants that will help propel innovative science and deliver hope to those facing the disease. These research grants support 25 cutting-edge projects at 17 prestigious institutions — marking a powerful commitment to improving outcomes for people living with breast cancer today and in the future.
'We are proud to support these exceptional researchers who are pushing the boundaries of what's possible in breast cancer science,' said Paula Schneider, President and CEO of Susan G. Komen. 'Research saves lives, and now more than ever, we must invest in science that brings hope to patients — especially those facing the most aggressive forms of breast cancer.'
Through this research investment, Komen is prioritizing the most pressing challenges facing patients, including metastatic breast cancer, health inequities and the need for more precise, personalized treatment strategies to improve care and outcomes for everyone impacted by breast cancer.
Key Highlights of Komen's 2025 Research Investment:
54% of funding targets metastatic breast cancer — the most advanced stage of the disease, responsible for the nearly 43,000 deaths each year in the U.S.
50% focused on precision medicine to tailor treatments to each patient's unique biology.
21% invested in addressing disparities to eliminate inequities in breast cancer care and outcomes.
25 researchers funded, including 10 early-career investigators, representing the next generation of scientific leaders.
'Komen's commitment to breast cancer research comes at a pivotal time and will drive meaningful advances in our understanding of the disease and care of patients,' said Ann Partridge, M.D., M.P.H., Chief Scientific Advisor for Komen. 'By fueling science that is both innovative and inclusive, we're accelerating progress where patients need it most — while building a foundation for individualized care for all.'
Komen is the largest nonprofit funder of breast cancer research outside the U.S. government, investing nearly $1.1 billion since its inception. Unlike many research institutions, Komen's work is powered entirely by the generosity of individual donors, corporate partners and community supporters.
'Investing in top scientific talent is one of the most powerful ways we can drive progress,' said Jennifer A. Pietenpol, Ph.D., Chief Scientific Advisor for Komen. 'Komen's commitment, especially to early-career researchers, cultivates a vibrant ecosystem where bold ideas and pioneering research can thrive, accelerating our path toward the cures we urgently seek.'
REACHing Deeper into Research Advocacy
Komen's commitment to research goes beyond funding — it includes empowering people to bring their lived experiences into the heart of science. Through its recently launched REACH (Research Education and Advocate Community Hub) initiative, Komen invites patients, survivors and co-survivors to become research advocates and help shape research. ShareforCures®, Komen's breast cancer registry, provides breast cancer patients and survivors with a new, secure and easy way to share health data to help accelerate breast cancer research.
As Komen deepens its investment in research, the need for collaboration — between scientists, clinicians, advocates and patients — has never been greater. Through strategic funding, innovative patient-centric scientific programs, robust advocacy programs, education and patient support services, Susan G. Komen is leading the way so patients can benefit from scientific breakthroughs and receive the care they need to live longer, healthier lives.
Recipients of Komen Grants
Recipients of Career Catalyst Research Grants
Chun-Kan Chen, PhD, MS, Washington University in St. Louis
Miriam Jacobs, MD, Georgetown University
Martina Molgora, PhD, MSc., H. Lee Moffitt Cancer Center & Research Institute, Inc.
Daniel O'Neil, MD, MPH, Yale University
Claire Sathe, MD, JD, Columbia University Irving Medical Center
Na Zhao, PhD, Baylor College of Medicine
Recipients of Career Transition Awards
Charles Dai, MD, Massachusetts General Hospital
Avantika Gupta, PhD, MSc, Memorial Sloan-Kettering Cancer Center
Alissa Michel, MD, Columbia University Irving Medical Center
Veena Padmanaban, PhD, MS, The Rockefeller University
Recipients of Leadership Grants
Alan Ashworth, PhD, University of California, San Francisco
Tuya Pal, MD, Vanderbilt University Medical Center
Rulla Tamimi, ScD, MS, Weill Medical College of Cornell University
Kornelia Polyak, MD, PhD, Dana-Farber Cancer Institute
Christina Curtis, PhD, MSc, Stanford University School of Medicine
Jeffrey Rosen, PhD, Baylor College of Medicine
Tracy Battaglia, MD, Yale University
Allison Kurian, MD, MSc, Stanford University School of Medicine
Nancy Lin, MD, Dana-Farber Cancer Institute
Ben Ho Park, MD, PhD, Vanderbilt University Medical Center
Jennifer Pietenpol, PhD, Vanderbilt University Medical Center
Recipients of Opportunity Grants
Filipa Lynce, MD, Dana Farber Cancer Institute
Michele Cote, PhD, MPH, Indiana University
Antonio Wolff, MD, Johns Hopkins University School of Medicine
Recipient of Scientific Strategy and Programs Grant
Adrian Lee, PhD, University of Pittsburgh
To learn more about Komen's research initiatives, visit komen.org/research. To explore how you can get involved with REACH (Research Education and Advocate Community Hub), visit komen.org/REACH
About Susan G. Komen ®
Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Vesta Announces Second Quarter 2025 Earnings Conference Call and Webcast
MEXICO CITY, June 23, 2025--(BUSINESS WIRE)--Corporación Inmobiliaria Vesta, S.A.B. de C.V. (NYSE: VTMX, BMV: VESTA) ("Vesta") announced today that the Company's Second Quarter 2025 financial results will be released after market close on Thursday, July 24, 2025. Vesta will host a conference call to discuss its results. Conference Call Details:Friday, July 25, 202511:00 a.m. ET / 9:00 a.m. Mexico City Time To participate in the conference call, please connect via webcast or by dialing: International Toll-Free: +1 (888) 350-3870 International Toll: +1 (646) 960-0308 International Numbers: Participant Code: 1849111 Webcast: The call replay will be available for one week following the conference call and can be accessed two hours after the call's completion via Vesta's IR website, along with the company's earnings press release, financial tables, and slide presentation. The call replay can also be accessed via +1-800-770-2030, Participant Code: 1849111 About Vesta Vesta is a real estate owner, developer and asset manager of industrial buildings and distribution centers in Mexico. As of March 31, 2025, Vesta owned 228 properties located in modern industrial parks in 16 states of Mexico totaling a GLA of 41.2 million sf (3.7 million m2). Vesta has several world-class clients participating in a variety of industries such as automotive, aerospace, retail, high-tech, pharmaceuticals, electronics, food and beverage, and packaging. For additional information visit: View source version on Contacts Investor Relations ContactIn Mexico: Juan Sottil, CFO jsottil@ Tel: +52 55 5950-0070 ext. 133Fernanda Bettinger, IRO mfbettinger@ Tel: +52 55 5950-0070 ext. 163In New York: Barbara Cano barbara@ Tel: +1 646-452-2334
Business Wire
32 minutes ago
- Business Wire
Vesta Announces Second Quarter 2025 Earnings Conference Call and Webcast
MEXICO CITY--(BUSINESS WIRE)--Corporación Inmobiliaria Vesta, S.A.B. de C.V. (NYSE: VTMX, BMV: VESTA) ("Vesta") announced today that the Company's Second Quarter 2025 financial results will be released after market close on Thursday, July 24, 2025. Vesta will host a conference call to discuss its results. Conference Call Details: 11:00 a.m. ET / 9:00 a.m. Mexico City Time To participate in the conference call, please connect via webcast or by dialing: The call replay will be available for one week following the conference call and can be accessed two hours after the call's completion via Vesta's IR website, along with the company's earnings press release, financial tables, and slide presentation. The call replay can also be accessed via +1-800-770-2030, Participant Code: 1849111 About Vesta Vesta is a real estate owner, developer and asset manager of industrial buildings and distribution centers in Mexico. As of March 31, 2025, Vesta owned 228 properties located in modern industrial parks in 16 states of Mexico totaling a GLA of 41.2 million sf (3.7 million m2). Vesta has several world-class clients participating in a variety of industries such as automotive, aerospace, retail, high-tech, pharmaceuticals, electronics, food and beverage, and packaging. For additional information visit:
Business Wire
32 minutes ago
- Business Wire
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym ® in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes at the American Diabetes Association's 85 th Scientific Sessions. CATALYST met its primary endpoint. Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c (HbA1c), which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo (p-value: < 0.001). Of the 91 patients in the treatment group, 65 (71%) received at least 600mg of Korlym and 28 (31%) received 900mg. Patients who received 900mg of Korlym had an improvement in HbA1c of 2.01 percent, compared to a 0.16 percent decrease in patients who received placebo (p-value: < 0.001). The trial also met its secondary endpoints, as patients who received Korlym exhibited significantly reduced body weight (5.1 kg; p-value: 0.001) and waist circumference (5.1 cm; p-value: 0.002), compared to patients who received placebo. Patients receiving Korlym achieved these improvements despite reducing or discontinuing their glucose-lowering medications. Adverse events in CATALYST were manageable and consistent with Korlym's known safety profile. The most common adverse events (> 20% of participants receiving Korlym) were hypokalemia, fatigue and nausea. The conference presentations can be found here. Results were published simultaneously in Diabetes Care, in an article titled ' Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.' CATALYST is the largest and most rigorous trial ever conducted to determine the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and assess the effect of treating patients found to have hypercortisolism with a cortisol modulator. The initial prevalence phase of the trial screened 1,057 patients with difficult-to-control type 2 diabetes (i.e., patients with HbA1c greater than 7.5 percent despite receiving multiple glucose-lowering medications, including best-in-class therapies such as GLP-1 agonists) at 36 sites in the United States. Based on results from a standard 1-mg dexamethasone suppression test, 24 percent of the patients screened were found to have hypercortisolism and were eligible to enter the trial's treatment phase, where they were randomized, 2:1, to receive either Korlym or placebo for 24 weeks. One hundred thirty-six patients enrolled in the treatment phase. 'Many people with type 2 diabetes do not respond adequately to conventional glucose-lowering therapies,' said John Buse, M.D., Ph.D., director of the University of North Carolina's Diabetes Center. 'CATALYST shows that these patients should be screened for hypercortisolism and that treatment with a cortisol-directed therapy can confer significant clinical benefits, including meaningful reductions in HbA1c, body weight and waist circumference. These powerful findings provide important guidance for physicians treating patients with difficult-to-control type 2 diabetes.' 'We urgently need all physicians, not just endocrinologists, to develop a greater understanding of Cushing's syndrome,' said Leslie Edwin, President of the Cushing's Support & Research Foundation. 'As a person who has lived with the complex and far-reaching effects of Cushing's syndrome for almost two decades, it is difficult to see that some things have been slow to change. Patients are still spending years on average searching for the cause of deceptively common symptoms, like elevated blood sugar, weight gain, depression and anxiety treated as individual diagnoses instead of parts of a bigger, more burdensome problem that carries tremendous health risk. The CATALYST data will help physicians identify and treat patients more quickly and accurately through earlier screening, and that is such an exciting prospect for all of us in the Cushing's community.' 'The CATALYST results will help physicians more accurately diagnose and treat people with hypercortisolism, a serious and deadly disease that too often goes undetected,' said Bill Guyer, PharmD, Corcept's Chief Development Officer. 'One in four patients with difficult-to-control type 2 diabetes have hypercortisolism and treatment with a cortisol modulator can be highly effective in improving many of their signs and symptoms. Corcept is thankful to the patients who participated in CATALYST. We hope these data can help all patients with this disease.' About Hypercortisolism (Cushing's Syndrome) Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be lethal if not treated effectively. IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. IMPORTANT LIMITATIONS OF USE Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome. BOXED WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a nonhormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential. DOSAGE AND ADMINISTRATION Obtain a negative pregnancy test prior to initiating treatment with Korlym in females of reproductive potential, or if treatment is interrupted for more than 14 days. Administer once daily orally with a meal. The recommended starting dose is 300 mg once daily. Renal impairment: Do not exceed 600 mg once daily. Mild-to-moderate hepatic impairment: Do not exceed 600 mg once daily. Do not use in severe hepatic impairment. Based on clinical response and tolerability, the dose may be increased in 300-mg increments to a maximum of 1200 mg once daily. Do not exceed 20 mg/kg per day. Concomitant use of Korlym with a strong CYP3A inhibitor resulted in a 38% increase in mean plasma concentration of mifepristone. For patients already being treated with a strong CYP3A inhibitor, start with a Korlym dose of 300 mg per day and titrate to a maximum of 900 mg per day if clinically indicated. When a strong CYP3A inhibitor is administered to patients already receiving Korlym, adjust the dose as follows: for patients receiving a daily dose of 600 mg, reduce dose to 300 mg. For patients receiving a daily dose of 900 mg, reduce dose to 600 mg. For patients receiving a daily dose of 1200 mg, reduce dose to 900 mg. Titrate if clinically indicated and do not exceed a Korlym dose of 900 mg in combination with a strong CYP3A inhibitor. CONTRAINDICATIONS Pregnancy; patients taking simvastatin or lovastatin and CYP3A substrates with narrow therapeutic ranges; patients receiving systemic corticosteroids for lifesaving purposes; women with a history of unexplained vaginal bleeding or endometrial hyperplasia with atypia or endometrial carcinoma; patients with known hypersensitivity to mifepristone or to any of the product components. WARNINGS AND PRECAUTIONS Adrenal insufficiency: Patients should be closely monitored for signs and symptoms of adrenal insufficiency. Hypokalemia: Hypokalemia should be corrected prior to treatment and monitored for during treatment. Vaginal bleeding and endometrial changes: Women may experience endometrial thickening or unexpected vaginal bleeding. Use with caution if the patient also has a hemorrhagic disorder or is on anticoagulant therapy. QT interval prolongation: Avoid use with QT interval-prolonging drugs, or in patients with potassium channel variants resulting in a long QT interval. Use of strong CYP3A inhibitors: Concomitant use increases mifepristone plasma levels. Adjust Korlym dose as described in Dosage and Administration. Use only when necessary and do not exceed a Korlym dose of 900 mg. ADVERSE REACTIONS Most common adverse reactions in Cushing's syndrome (≥20%): nausea, fatigue, headache, decreased blood potassium, arthralgia, vomiting, peripheral edema, hypertension, dizziness, decreased appetite, endometrial hypertrophy. DRUG INTERACTIONS Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with Korlym. CYP3A inhibitors: Caution should be used when Korlym is used with strong CYP3A inhibitors. Adjust Korlym dose as described in Dosage and Administration. Use only when necessary, and do not exceed a Korlym dose of 900 mg. CYP3A inducers: Do not use Korlym with CYP3A inducers. Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used with Korlym. Drugs metabolized by CYP2B6: Use of Korlym should be done with caution with bupropion and efavirenz. Hormonal contraceptives: Do not use with Korlym. USE IN SPECIFIC POPULATIONS Lactation: Mifepristone is present in human milk, however, there are no data on the amount of mifepristone in human milk, the effects on the breastfed infant, or the effects on milk production during long term use of mifepristone. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, those related to our ability to: operate our business; study and develop Korlym ®, relacorilant, miricorilant, dazucorilant and our other product candidates; those molecules' clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include: the impact of CATALYST on the medical field's practices regarding the screening for and treatment of hypercortisolism. We disclaim any intention or duty to update forward-looking statements made in this press release.
